ESMO Media Releases

The incoming wave of biosimilars in oncology is the focus of a Special Session at the ESMO 2017 Congress in Madrid.

Some stroke survivors may have underlying cancer, according to an observational study to be presented at the ESMO 2017 Congress in Madrid.

Data from two separate phase 3 studies to be presented at the ESMO 2017 Congress in Madrid, show alectinib’s particular central nervous system (CNS) activity in patients with advanced non-small cell lung cancer involving a mutation of the anaplastic lymphoma kinase gene (ALK-positive NSCLC). 

Patients requiring surgery for oesophageal cancer fare better after undergoing a hybrid minimally invasive oesophagectomy (HMIO) compared to an open oesophagectomy (OO), according to long-term results of the MIRO trial to be presented at the ESMO 2017 Congress in Madrid.

European women with ovarian cancer can safely stick to the standard three-week dosing schedule for paclitaxel rather than boosting up to a weekly dose-dense regimen, according to results of the phase III ICON8 trial to be presented at the ESMO 2017 Congress in Madrid.

Even small tumours can be aggressive, according to a study in patients with early stage breast cancer that will be presented at the ESMO 2017 Congress in Madrid. Researchers found that nearly one in four small tumours were aggressive and patients benefited from chemotherapy. Aggressive tumours could be identified by a 70-gene signature.

The vast majority of tumour marker tests in primary and secondary care are not necessary, according to a study that will be presented at the ESMO 2017 Congress in Madrid. The tests assisted with a cancer diagnosis in just 2% of patients.

An updated version of the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) will enable users to evaluate single-arm studies for the first time.

The optimal follow-up protocol for patients with completely resected non-small cell lung cancer (NSCLC) remains elusive after results of the IFCT-0302 trial, presented at the ESMO 2017 Congress in Madrid (1), did not show a difference in overall survival (OS) between patients who received computed tomography (CT) scans as part of their follow-up, and those who did not.

Abstracts accepted as oral presentations and posters at the ESMO 2017 Congress will be published online at 00:05 CEST on 31 August 2017. 

ESMO 2017 is once again the place to be for breaking news on cancer research. ESMO 2017, the annual oncology congress organised by the European Society for Medical Oncology (ESMO) in partnership with the European Association for Cancer Research (EACR) will take place in Madrid, Spain, from 8 to 12 September at IFEMA, Feria de Madrid.

Three leading European organisations in the fight against cancer have called the EU to urgently increase its support for independent academic research for the benefit of cancer patients, in an article published today in ESMO Open.